Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galapagos NV filings document foreign-issuer disclosures made primarily on Form 6-K, including material events, shareholder meeting results, governance actions, capital-structure updates and clinical or regulatory communications. The records cover annual and extraordinary meeting votes, remuneration and board matters, subscription right plans, registration-statement incorporation, and transparency notifications under Belgian ownership-disclosure rules.
The company’s filings also include press releases and corporate presentations related to strategic collaborations, T cell engager and cell-therapy programs, operating and financial results, and shareholder voting mechanics. For this ADR-listed biotechnology issuer, the filing record ties business development, pipeline disclosures, ownership thresholds, employee equity instruments and corporate-governance approvals to formal U.S. securities reporting.
Galapagos NV, a foreign private issuer based in Mechelen, Belgium, submitted a Form 6-K for October 2025. The company states it files annual reports on Form 20-F. The report primarily furnishes a press release dated October 30, 2025 as Exhibit 99.1.
The information in this Form 6-K, including Exhibit 99.1 but excluding the quoted statements of Jérôme Contamine and Henry Gosebruch, is incorporated by reference into multiple existing Galapagos Form S-8 registration statements. This filing is mainly an administrative update linking the new disclosure to prior employee equity plan registrations.
Galapagos NV (GLPG) furnished a Form 6‑K as a foreign private issuer. The report attaches a press release dated October 23, 2025 as Exhibit 99.1 and incorporates it by reference into the company’s Registration Statements on Form S‑8.
The company indicates it files annual reports under cover of Form 20‑F. The Form 6‑K was signed by Company Secretary Annelies Denecker on October 24, 2025.
Galapagos NV filed a Form 6-K as a foreign private issuer, stating that it reports under Form 20-F. The company furnished a press release dated October 21, 2025 as Exhibit 99.1, and specified that the information in this report, except for certain quoted statements, is incorporated by reference into multiple existing employee share plan registration statements on Form S-8.
Galapagos NV furnished a Form 6-K and attached a press release dated October 16, 2025 as Exhibit 99.1.
The company states that the information in this report, including Exhibit 99.1, except for quotes by Henry Gosebruch and Fred Blakeslee, is incorporated by reference into its Registration Statements on Form S-8. Galapagos files annual reports on Form 20-F.
EcoR1 Capital files Amendment No. 3 to Schedule 13D on Galapagos NV (GLPG). The biotech-focused hedge fund and its founder Oleg Nodelman now report beneficial ownership of 8,714,522 ordinary shares/ADSs, equal to 13.22 % of the 65,897,071 shares outstanding (Form 20-F, 31 Dec 2024). The position is concentrated in EcoR1 Capital Fund Qualified, L.P. (8.19 m shares, 12.43 %) while EcoR1 Capital Fund, L.P. holds 0.52 m shares (0.79 %).
The shares were accumulated for an aggregate US$399.4 million; an additional US$293,693 in fees was paid to Citibank for converting ADSs into ordinary shares. EcoR1 and Mr Nodelman have shared voting and dispositive power over the entire stake.
Apart from updating share totals and cost, the filing makes no changes to the previously stated purpose of the investment or to any contracts, arrangements or relationships with the issuer. Exhibit 99.2 details trades executed in the past 60 days; no other transactions were disclosed.